Evommune (EVMN) Income from Continuing Operations (2024 - 2026)
Evommune (EVMN) posted quarterly Income from Continuing Operations of 113645000.0 for Q1 2026, down 677.38% year-over-year from 19682920.31 in Q1 2025, and down 302.57% quarter-over-quarter from 28230000.0 in Q4 2025.
Evommune (EVMN) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Evommune (EVMN) has reported Income from Continuing Operations for 3 consecutive years, with 113645000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 677.38% year-over-year to 113645000.0; the TTM figure through Mar 2026 stood at 175868000.0 (changed N/A YoY), while the FY2025 annual figure was 132251000.0, down 95.72% from the prior year.
- Income from Continuing Operations retreated to 113645000.0 in Q1 2026 per EVMN's latest filing, from 28230000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 14619000.0 in Q1 2025 and bottomed at 113645000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 35419500.0 across 3 years, with a median of 20053500.0 in 2024.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations slipped 21.73% — and 2026, when it plunged 677.38%.
- Evommune's Income from Continuing Operations stood at 20733000.0 in 2024, then sank by 36.16% to 28230000.0 in 2025, then plunged by 302.57% to 113645000.0 in 2026.
- Business Quant data shows EVMN's Income from Continuing Operations at 113645000.0 in Q1 2026, 28230000.0 in Q4 2025, and 19374000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Evommune | 531.53 Mn | 330.73 Mn | - | -67.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -67.55 Mn |
| Mar 31, 2026 | -113.65 Mn |
| Dec 31, 2025 | -28.23 Mn |
| Sep 30, 2025 | -19.37 Mn |
| Mar 31, 2025 | -14.62 Mn |
| Dec 31, 2024 | -20.73 Mn |
| Sep 30, 2024 | -15.92 Mn |